by Eclosion Team | Jan 31, 2020 | Uncategorized
Geneva, Switzerland, January 31, 2020 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases (the...
by Eclosion Team | Dec 3, 2019 | Uncategorized
Phase 2 DKD trial funded by JDRF to expand in Europe and New Zealand 13 patients have completed full 48-week treatment in DKD trial; no safety signals identified Phase 2 IPF trial funded by NIH; poised to initiate patient enrollment following recently received FDA and...
by Eclosion Team | Nov 25, 2019 | Uncategorized
Collaboration follows data from ANGEL-MS extension to Phase 2 MS trial Aims to address key unmet need of slowing or stopping disease progression Geneva, Switzerland, November 25, 2019 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO),...
by Eclosion Team | Oct 31, 2019 | Uncategorized
A must-attend and rapidly growing event with experts around the world: 36 speakers from 10 countries In-depth scientific review of the role played by the HERVs in a broad range of diseases including multiple sclerosis, amyotrophic lateral sclerosis and cancer Focus on...
by Eclosion Team | Sep 16, 2019 | Uncategorized
Further evidence adds to already strong set of positive clinical data Data presented at ECTRIMS 2019 Congress in Stockholm, Sweden Geneva, Switzerland, September 16, 2019 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company...
